OncoTartis, Inc. has engaged Dr. Eric Rowinsky to serve an acting Medical Director for the upcoming clinical trial of its drug candidate OT-82, a small molecule with anti-leukemia and anti-lymphoma activities. Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading the Food and Drug Administration, or FDA, approval of Erbitux® for head and neck and colorectal cancers and advancing eight other biological therapeutics through clinical development while at ImClone. He completed a medical oncology fellowship at The Johns Hopkins Hospital. Dr. Rowinsky was an Associate Professor of Oncology at [...]
OncoTartis has concluded a $6 million financing round to support the Phase 1 clinical trial of the lead drug candidate OT-82.
OncoTartis Closes $6M Financing Round. BUFFALO, N.Y., Dec. 11, 2017 /PRNewswire/ -- OncoTartis, Inc., a biotechnology company developing a novel category of anti-cancer drugs, has concluded a $6 million financing round to support the Phase 1 clinical trial of its lead drug candidate, OT-82. Participants in the round included Norma Investments, representing businessman Roman Abramovich, and Pharmstandard International S.A., a venture arm of the largest Russian pharmaceutical company, based in Luxembourg. OT-82 has been isolated for its selective toxicity for a broad range of hematological malignancies. The drug candidate, a Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, has demonstrated high efficacy in a variety [...]
OT-82 shows impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients
The Preclinical Testing Consortium (PPTC) is a US National Cancer Institute-funded initiative aimed at prioritizing effective drugs for clinical evaluation in pediatric cancers. OT-82 was selected for testing into this program. Results obtained with OT-82 showed impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients. In addition, OT-82 demonstrated synergy with AraC in combination therapy. Consequently NAMPT inhibition by OT-82 is an attractive strategy for treating leukemia, and these data support further evaluation of this drug in the treatment of high-risk pediatric ALL.
OncoTartis have successfully completed preclinical GLP Toxicology, Pharmacokinetics and Safety studies
OncoTartis have successfully completed preclinical GLP Toxicology, Pharmacokinetics and Safety studies demonstrating wide therapeutic window of OT-82. In the course of the studies, no ophthalmic toxicity in monkeys and mice was found. The drug did not show any cardiac toxicity in monkey either. Based on the results of pre-clinical studies as well as GLP studies, a dose range for Phase 1 clinical trials was calculated. This trial will open in the beginning of 2018 and first signs of efficacy are projected to be seen already in the first cohorts.